You have 9 free searches left this month | to do more

elotuzumab

Elotuzumab is a drug used to treat Multiple Myeloma, Plasma Cell Myeloma, AML, Adult, and other conditions. Elotuzumab is being actively studied in 24 studies and prior, has been studied in 7.

Top SponsorsTop SitesTop Investigators
Bristol-Myers SquibbLocal InstitutionJacob Laubach
Dana-Farber Cancer InstituteMassachusetts General HospitalAndrew Yee, MD
University of ArkansasColorado Blood Cancer InstituteBinod Dhakal
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED
N
Recruiting
  • IgG4 Related Disease
  • IgG4-RD
  • elotuzumab
  • +6 more
  • Atlanta, Georgia
  • +2 more
2021-10-13
Oct 13, 2021
N
Withdrawn
  • Multiple Myeloma
  • (no location specified)
2021-08-18
Aug 18, 2021
Y
Not yet recruiting
  • Multiple Myeloma
  • Elotuzumab
  • Belantamab mafodotin
  • New Haven, Connecticut
    Yale New Haven Hospital
2021-08-11
Aug 11, 2021
H
Active, not recruiting
  • Multiple Myeloma
  • Elotuzumab
  • +2 more
  • Tampa, Florida
    H. Lee Moffitt Cancer Center and Research Institute
2021-06-11
Jun 11, 2021
M
Not yet recruiting
  • Multiple Myeloma
  • Isatuximab (for run-in portion)
  • +4 more
  • Milwaukee, Wisconsin
    Froedtert Hospital & the Medical College of Wisconsin
2021-09-22
Sep 22, 2021
M
Active, not recruiting
  • Hematopoietic Cell Transplantation Recipient
  • Plasma Cell Myeloma
  • Elotuzumab
  • +2 more
  • Houston, Texas
    M D Anderson Cancer Center
2020-10-20
Oct 20, 2020
D
Active, not recruiting
  • Multiple Myeloma
  • Atlanta, Georgia
  • +6 more
2021-02-09
Feb 9, 2021
U
Withdrawn
  • Multiple Myeloma
  • Elotuzumab
  • +4 more
  • Little Rock, Arkansas
    University of Arkansas for Medical Sciences
2020-07-08
Jul 8, 2020
B
Terminated
  • Newly Diagnosed, Previously Untreated Multiple Myeloma
  • San Francisco, California
  • +13 more
2021-06-29
Jun 29, 2021
M
Active, not recruiting
  • Multiple Myeloma
  • Elotuzumab
  • Charlotte, North Carolina
    Levine Cancer Institute
2021-10-01
Oct 1, 2021
D
Active, not recruiting
  • Smoldering Myeloma
  • Smoldering Multiple Myeloma
  • Elotuzumab
  • +2 more
  • Denver, Colorado
  • +8 more
2021-09-13
Sep 13, 2021
B
Active, not recruiting
  • Recurrent Primary Amyloidosis
  • Duarte, California
  • +4 more
2021-03-10
Mar 10, 2021
B
Active, not recruiting
  • Multiple Myeloma
  • Elotuzumab
  • +5 more
  • Tucson, Arizona
  • +28 more
2021-08-17
Aug 17, 2021
A
Withdrawn
  • Multiple Myeloma
  • Elotuzumab
  • Paris, France
    Hématologie et thérapie cellulaire, Hôpital Saint Antoine
2019-07-15
Jul 15, 2019
O
Active, not recruiting
  • Multiple Myeloma
  • Elotuzumab
  • +3 more
  • Encinitas, California
  • +5 more
2020-08-12
Aug 12, 2020
W
Recruiting
  • Newly Diagnosed Multiple Myeloma
  • Elotuzumab
  • +4 more
  • Krems, Lower Austria, Austria
  • +55 more
2021-02-25
Feb 25, 2021
M
Unknown status
  • Multiple Myeloma
  • Elotuzumab
  • +3 more
  • Boston, Massachusetts
  • +5 more
2019-08-12
Aug 12, 2019
U
Suspended
  • Multiple Myeloma
  • Elotuzumab
  • +3 more
  • Chicago, Illinois
  • +2 more
2021-06-24
Jun 24, 2021
W
Recruiting
  • Multiple Myeloma in Relapse
  • Elotuzumab
  • +2 more
  • Denver, Colorado
  • +3 more
2021-06-30
Jun 30, 2021
S
Active, not recruiting
  • Multiple Myeloma
  • elotuzumab
  • +3 more
  • Denver, Colorado
  • +5 more
2021-08-12
Aug 12, 2021
M
Recruiting
  • Refractory Plasma Cell Myeloma
  • Jacksonville, Florida
    Mayo Clinic in Florida
2021-02-24
Feb 24, 2021
M
Recruiting
  • Plasma Cell Leukemia
  • Plasma Cell Myeloma
  • Autologous Hematopoietic Stem Cell Transplantation
  • +6 more
  • Houston, Texas
    M D Anderson Cancer Center
2021-07-12
Jul 12, 2021